Edelstein M - Search Results

1

Discovery and development of anticancer agents from marine sponges: perspectives based on a chemistry-experimental therapeutics collaborative program.

Valeriote FA, Tenney K, Media J, Pietraszkiewicz H, Edelstein M, Johnson TA, Amagata T, Crews P. Valeriote FA, et al. Among authors: edelstein m. J Exp Ther Oncol. 2012;10(2):119-34. J Exp Ther Oncol. 2012. PMID: 23350352

2

Quantitative measurements of the efficacy of new anti-cancer agents on fresh human AML cells by using multivariate flow analysis.

Nakeff A, KuKuruga MA, Media JE, Valeriote F, Edelstein MB. Nakeff A, et al. Among authors: edelstein mb. J Exp Ther Oncol. 1996 Nov;1(6):361-7. J Exp Ther Oncol. 1996. PMID: 9414426

3

Synthesis and Biological Evaluation of Novel N-phenyl-5-carboxamidyl Isoxazoles as Potential Chemotherapeutic Agents for Colon Cancer.

Shaw J, Chen B, Bourgault JP, Jiang H, Kumar N, Mishra J, Valeriote FA, Media J, Bobbitt K, Pietraszkiewicz H, Edelstein M, Andreana PR. Shaw J, et al. Among authors: edelstein m. Am J Biomed Sci. 2012;4(1):14-25. doi: 10.5099/aj120100014. Am J Biomed Sci. 2012. PMID: 25285182 Free PMC article.

4

Interrogating the bioactive pharmacophore of the latrunculin chemotype by investigating the metabolites of two taxonomically unrelated sponges.

Amagata T, Johnson TA, Cichewicz RH, Tenney K, Mooberry SL, Media J, Edelstein M, Valeriote FA, Crews P. Amagata T, et al. Among authors: edelstein m. J Med Chem. 2008 Nov 27;51(22):7234-42. doi: 10.1021/jm8008585. J Med Chem. 2008. PMID: 18942825 Free PMC article.

5

New in vitro screening model for the discovery of antileukemic anticancer agents.

Valeriote F, Corbett T, Edelstein M, Baker L. Valeriote F, et al. Among authors: edelstein m. Cancer Invest. 1996;14(2):124-41. doi: 10.3109/07357909609018888. Cancer Invest. 1996. PMID: 8597898 No abstract available.

6

In vitro screening model for the detection of agents active against myelogenous leukemia.

Edelstein M, Corbett T, Valeriote F. Edelstein M, et al. Cancer Invest. 1998;16(5):303-8. doi: 10.3109/07357909809084648. Cancer Invest. 1998. PMID: 9627676

7

The role of cell kinetics in cancer chemotherapy.

Valeriote FA, Edelstein MB. Valeriote FA, et al. Among authors: edelstein mb. Semin Oncol. 1977 Jun;4(2):217-26. Semin Oncol. 1977. PMID: 327554 Review. No abstract available.

8

Cytosine arabinoside in experimental combination therapy.

Edelstein M, Valeriote F. Edelstein M, et al. Semin Oncol. 1985 Jun;12(2 Suppl 3):75-83. Semin Oncol. 1985. PMID: 3892705 Review. No abstract available.

9

Retention of 1-beta-D-arabinofuranosylcytosine in vitro--a source of experimental error.

Edelstein M, Valeriote F. Edelstein M, et al. Biochem Pharmacol. 1977 Mar 15;26(6):477-80. doi: 10.1016/0006-2952(77)90320-3. Biochem Pharmacol. 1977. PMID: 849343 No abstract available.

10

Alteration of the bis-tetrahydrofuran core stereochemistries in asimicin can affect the cytotoxicity.

Sinha SC, Chen Z, Huang ZZ, Nakamaru-Ogiso E, Pietraszkiewicz H, Edelstein M, Valeriote F. Sinha SC, et al. Among authors: edelstein m. J Med Chem. 2008 Nov 27;51(22):7045-8. doi: 10.1021/jm801028c. J Med Chem. 2008. PMID: 18975929 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

337 results

Search Page

Filters